TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23281132

Group type: EXPERIMENTAL
Intervention: 320 mg Bacopa monnieri (BM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 640 mg Bacopa monnieri (BM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19217460

Group type: EXPERIMENTAL
Intervention: Low-dose pravastatin (10 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-dose pravastatin (40 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 21
Study: 17313292

Group type: EXPERIMENTAL
Intervention: Ballistic strength training (BST)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 15196159

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole daily
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 400 mg itraconazole daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 12068841

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 0
Study: 9793702

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray (20 mg/dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Subcutaneous injection of sumatriptan
Number of subjects: 26
Study: 7620630

Group type: EXPERIMENTAL
Intervention: Laufband therapy (LB) with body weight support (BWS) and assisted limb movements
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Laufband therapy (LB)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 89
Study: 2515583

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-Roferon (R-IFN) applied as ointment, 20,000 IU/g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-Ginterferon (G-IFN) applied as ointment, 10,000 IU/g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both R-IFN and G-IFN
Number of subjects: 0
Study: 341943

Group type: EXPERIMENTAL
Intervention: Mianserin (GB‐94)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31765640

Group type: COMPARATOR
Intervention: Oral placebo plus education only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loperamide plus education only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral placebo plus biofeedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loperamide plus biofeedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responders to fecal incontinence treatment
Number of subjects: 0
Study: 30704287

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg od plus a P2Y12 inhibitor (group 1)
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (group 2)
Number of subjects: 2124

Group type: COMPARATOR
Intervention: Warfarin plus dual antiplatelet therapy (group 3)
Number of subjects: 2124
Study: 27531675

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose (150-600 mg/d)
Number of subjects: 2011

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2011
Study: 25564832

Group type: EXPERIMENTAL
Intervention: Skills-based breast self-exam (BSE)/testicular self-exam (TSE) training
Number of subjects: 1058
Study: 24399120

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg for 15 days + Serenoa repens extract for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prulifloxacin 600 mg for 15 days
Number of subjects: 56
Study: 21871782

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 500mg three times daily for 2 days, then oral amoxicillin for 3 more days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intravenous ampicillin 1g four times daily for 2 days, then oral amoxicillin for 3 more days
Number of subjects: 42
Study: 18826492

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (low-fat)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (high-fat)
Number of subjects: 55

Group type: COMPARATOR
Intervention: High-carbohydrate low-fat diet
Number of subjects: 55
Study: 17599747

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (10 mg bipuvicaine, 40 mg triamcinolone hexacetonide)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (10 mg bipuvicaine, 2 ml saline)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 52
Study: 15889559

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 70
Study: 11593094

Group type: EXPERIMENTAL
Intervention: Felodipine (with possible additional medications: ACE-inhibitor, beta-blocker, diuretic)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 347
Study: 9869994

Group type: EXPERIMENTAL
Intervention: Unipolar mode at atrial sensitivities of 0.625‐1.50 mV
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bipolar mode at atrial sensitivities of 0.625‐1.50 mV
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Unipolar mode at sensitivities of > 1.50 mV
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Optimal sensitivity settings for unipolar leads during AECG monitoring
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bipolar mode during AECG monitoring
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Unipolar mode for atrial leads
Number of subjects: 34

Group type: COMPARATOR
Intervention: Bipolar mode for atrial leads
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Unipolar mode for ventricular leads
Number of subjects: 34
Study: 8017036

Group type: EXPERIMENTAL
Intervention: Psychological Relaxation Therapy (PRT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No Psychological Relaxation Therapy (Control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 124
Study: 2542629

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg daily) with flunarizine (10 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30039986

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg·kg-1
Number of subjects: 22
Study: 28517955

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT) with prompt revascularization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT) alone
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Current and former smokers
Number of subjects: 2368
Study: 25376536

Group type: EXPERIMENTAL
Intervention: Dental floss impregnated with 5% chlorhexidine gluconate, used twice a day for 15 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waxed floss without impregnation, used twice a day for 15 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No interproximal cleaning (negative control)
Number of subjects: 30
Study: 23392665

Group type: EXPERIMENTAL
Intervention: Tinnitus ears (n = 124)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Non-tinnitus ears (n = 106)
Number of subjects: 230
Study: 21324888

Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9 kg/m² (minimally adjusted model)
Number of subjects: 6082

Group type: EXPERIMENTAL
Intervention: BMI 30.0-39.9 kg/m² (maximally adjusted model)
Number of subjects: 6082

Group type: COMPARATOR
Intervention: BMI 25-27.4 kg/m² (referent group)
Number of subjects: 6082
Study: 19454860

Group type: EXPERIMENTAL
Intervention: Multiple-dose LRPT 40 mg/d for 12 days with coadministered single-dose warfarin 30 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Single-dose warfarin 30 mg alone
Number of subjects: 13
Study: 17678656

Group type: EXPERIMENTAL
Intervention: CIMT (constraint‐induced movement therapy)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional intervention (control treatment)
Number of subjects: 47
Study: 15201103

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ultrasound therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ultra short‐wave electrotherapy
Number of subjects: 68
Study: 12759515

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day plus acenocoumarol at a targeted INR of 2.4‐3.6
Number of subjects: 121

Group type: COMPARATOR
Intervention: Acenocoumarol alone at the same dosage
Number of subjects: 121
Study: 9523210

Group type: EXPERIMENTAL
Intervention: Jewish women with familial ovarian cancer
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Jewish women with a first-degree relative with ovarian cancer
Number of subjects: 471

Group type: COMPARATOR
Intervention: Non-Jewish women with a first-degree relative with ovarian cancer
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Jewish women with no first-degree relative with ovarian cancer
Number of subjects: 471
Study: 7907073

Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 MU 3 times weekly for 6 months)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Interferon alfa (12-month course: 3 MU 3 times weekly for the first 6 months, 2 MU for the following 3 months, and 1 MU for the last 3 months)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Interferon alfa (both regimens)
Number of subjects: 108
Study: 2766862

Group type: EXPERIMENTAL
Intervention: High-dose cis-platinum (120 mg/m2) combined with cyclophosphamide (600 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cis-platinum (60 mg/m2) combined with cyclophosphamide (600 mg/m2)
Number of subjects: 0
Study: 19348

Group type: EXPERIMENTAL
Intervention: Gastropulgit Gel (liquid antacid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salicylate alone
Number of subjects: 0
Study: 29042358

Group type: EXPERIMENTAL
Intervention: INF/SB2
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: INF/INF
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: SB2/SB2
Number of subjects: 396
Study: 27172277

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study: 23169901

Group type: EXPERIMENTAL
Intervention: Hyperalimentation (30% more PN macronutrients)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 142
Study: 22445501

Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1Ra)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1Ra
Number of subjects: 0
Study: 20628388

Group type: EXPERIMENTAL
Intervention: Yttrium-90 resin microspheres (median activity, 1.7 GBq; range, 0.9-2.2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Yttrium-90 resin microspheres
Number of subjects: 50
Study: 18072006

Group type: EXPERIMENTAL
Intervention: Videoconference support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular telephone support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current clinic review follow-up
Number of subjects: 0
Study: 16182635

Group type: EXPERIMENTAL
Intervention: IMM dietary recall
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interview-administered dietary recall (FIAS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Standardized portion sizes
Number of subjects: 80
Study: 15828162

Group type: EXPERIMENTAL
Intervention: Trial enrolment
Number of subjects: 0
Study: 10524635

Group type: COMPARATOR
Intervention: Glycyrrhizin (group G)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin plus ursodeoxycholic acid (group G+U)
Number of subjects: 170
Study: 8624427

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PF)
Number of subjects: 69
Study: 2041929

Group type: EXPERIMENTAL
Intervention: Patients with suspected acute myocardial infarction (MI)
Number of subjects: 397
Study: 7014277

Group type: EXPERIMENTAL
Intervention: 30 mg oxatomide b.i.d.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31300248

Group type: EXPERIMENTAL
Intervention: 1% sodium hypochlorite (NaOCl)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: qPCR-negative canals (S3)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: S3-positive canals with <3.12 × 10^3 bacterial cell counts
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Increasing the apical level of the root canal filling
Number of subjects: 52
Study: 28681387

Group type: EXPERIMENTAL
Intervention: Functional Chewing Training (FuCT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (classical oral motor exercises)
Number of subjects: 32
Study: 26373676

Group type: EXPERIMENTAL
Intervention: MYC-IG translocation patients treated with rituximab-anthracycline-based chemotherapy
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: MYC-IG translocation patients
Number of subjects: 774

Group type: COMPARATOR
Intervention: MYC-non-IG translocation patients
Number of subjects: 774
Study: 24364373

Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Patient characteristics
Number of subjects: 250
Study: 22463488

Group type: EXPERIMENTAL
Intervention: Tailored training of household heads about the proper use of LLITN and community network system.
Number of subjects: 21673

Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 21673
Study: 19631051

Group type: EXPERIMENTAL
Intervention: Relaxation training (imagination condition)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relaxation training (virtual reality condition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard hospital-based care (control)
Number of subjects: 60
Study: 17549864

Group type: EXPERIMENTAL
Intervention: Unilateral surgery
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 15226754

Group type: EXPERIMENTAL
Intervention: Iron supplementation (15 mg iron and multivitamins)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (multivitamins alone)
Number of subjects: 49
Study: 11445102

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily for 28 days
Number of subjects: 1010

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1010
Study: 9543270

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard community care
Number of subjects: 60
Study: 7993835

Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Etoposide and carboplatin (EC)
Number of subjects: 143
Study: 2465265

Group type: EXPERIMENTAL
Intervention: Inosine pranobex 3 g a day for four weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Inosine pranobex
Number of subjects: 55
Study: 31539674

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (with or without virtual reality)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 162
Study: 30457965

Group type: EXPERIMENTAL
Intervention: Biofeedback balance training using inertial sensors
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 15
Study: 28864749

Group type: EXPERIMENTAL
Intervention: Wuzhi tablet co-administration with tacrolimus
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype plus Wuzhi tablet co-administration guided dosing
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard dosing of tacrolimus (control group)
Number of subjects: 44
Study: 23114199

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver at a load of 40 mm Hg for 10 seconds
Number of subjects: 30
Study: 16322487

Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine (AMPH) with physiotherapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo with physiotherapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 10 mg dextroamphetamine (AMPH) with physiotherapy in moderate hemiparesis subgroup
Number of subjects: 71
Study: 12583865

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10539775

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-[1-(13)C]oxoproline and L-[3, 3-(2)H]cysteine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-[(15)N]oxoproline and L-[3,3-(2)H]cysteine
Number of subjects: 5
Study: 8758790

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of DDP (100mg/m2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous administration of DDP (100mg/m2)
Number of subjects: 16
Study: 1913123

Group type: EXPERIMENTAL
Intervention: Intra-arterial recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Streptokinase (Sk)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Number of subjects: 60
Study: 6749773

Group type: EXPERIMENTAL
Intervention: Atropine 0.13 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine 0.26 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Higher doses of atropine (exact dosage not specified)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31898516

Group type: EXPERIMENTAL
Intervention: Interaction Competencies with Children - for Teachers (ICC-T) intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Monitoring group (no intervention)
Number of subjects: 1200
Study: 31440032

Group type: EXPERIMENTAL
Intervention: IDP‐73152 mesylate 40-320 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: IDP‐73152 mesylate 640 mg (fed state)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 26320145

Group type: EXPERIMENTAL
Intervention: Dance-based exercise intervention for 3 months
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study: 26053170

Group type: EXPERIMENTAL
Intervention: SPD left‐side down (SPD‐L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SPD right‐side down (SPD‐R)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard wedge (W)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat (F)
Number of subjects: 20
Study: 23277897

Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (60 mcg/strain)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (15 mcg/strain)
Number of subjects: 195
Study: 21593294

Group type: EXPERIMENTAL
Intervention: Weight loss of 5 to <10% (mean 7.25±2.1 kg)
Number of subjects: 5145
Study: 19879995

Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine (10 microg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 microg MPL-SE adjuvant)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 microg LEISH-F1 protein alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study: 16930788

Group type: EXPERIMENTAL
Intervention: Traditional digital blocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single subcutaneous palmar injection blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palmar techniques (including single subcutaneous palmar block and transthecal block)
Number of subjects: 0
Study: 15521842

Group type: EXPERIMENTAL
Intervention: Prednisolone (2-month course)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (inactive Crohn's disease)
Number of subjects: 15
Study: 11744511

Group type: EXPERIMENTAL
Intervention: Diet History Questionnaire (DHQ)
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Block FFQ
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Willett FFQ
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: DHQ
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: All three FFQs (DHQ, Block, Willett)
Number of subjects: 1301
Study: 9331018

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (combined treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 0
Study: 8281056

Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Number of subjects: 224

Group type: COMPARATOR
Intervention: Light exercise
Number of subjects: 224
Study: 3120484

Group type: EXPERIMENTAL
Intervention: Epidural nicomorphine post-operatively
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intramuscular nicomorphine post-operatively
Number of subjects: 129
Study: 30206090

Group type: EXPERIMENTAL
Intervention: Mexiletine hydrochloride (300 mg/day) administered orally three times a day for 4 weeks (period 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered orally three times a day for 4 weeks (period 1)
Number of subjects: 0
Study: 26852276

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 465

Group type: COMPARATOR
Intervention: No Radiotherapy (no-RT)
Number of subjects: 465
Study: 24682569

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of ventricular rate (VR) during atrial fibrillation (AF)
Number of subjects: 1404
Study: 24347765

Group type: EXPERIMENTAL
Intervention: melatonin (6 mg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: gabapentin (600 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130